Filgrastim (Neupogen, granulocyte-colony stimulating factor) is among the few countermeasures recommended for management of patients in the event of lethal total-body irradiation. Despite the plethora of studies using filgrastim as a radiation countermeasure, relatively little is known about the optimal dose schedule of filgrastim to mitigate radiation lethality. We evaluated the efficacy of filgrastim in improving 30-day survival of CD2F1 mice irradiated with a lethal dose (LD) in the AFRRI cobalt-60 facility. We tested different schedules of 1, 3, 5, 10 or 16 once-daily injections of filgrastim initiated one day after irradiation. Time optimization studies with filgrastim treatment were also performed, beginning 6-48 h postirradiation. Maximum survival was observed with 3 daily doses of 0.17 mg/kg filgrastim. Survival efficacy of the 3-day treatment was compared against the conventional 16-day filgrastim treatment after irradiation in four mouse strains with varying radiation sensitivities: C3H/HeN, C57BL/6, B6C3F1 and CD2F1. Blood indices, bone marrow histopathology and colony forming unit assays were also evaluated. Filgrastim significantly increased 30-day survival (P < 0.001) with a 3-day treatment compared to 16-day treatment. Filgrastim did not prevent cytopenia nadirs, but facilitated faster recovery of white blood cells, neutrophils, red blood cells, platelets, lymphocytes and hematocrits in all four strains. Accelerated hematopoietic recovery was also reflected in faster bone marrow reconstitution and significant increase in hematopoietic progenitors (P < 0.001) in all four mouse strains. These data indicate that prompt and abbreviated filgrastim treatment has potential benefit for triage in the event of a radiological incident for treating acute hematopoietic syndrome.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5539877PMC
http://dx.doi.org/10.1667/RR14555.1DOI Listing

Publication Analysis

Top Keywords

filgrastim
12
mouse strains
12
filgrastim treatment
12
abbreviated filgrastim
8
hematopoietic recovery
8
irradiation mouse
8
studies filgrastim
8
30-day survival
8
3-day treatment
8
treatment compared
8

Similar Publications

Background: To minimize adverse events of peripheral blood stem cell (PBSC) collection in healthy donors, it is reasonable to limit the total dose of granulocyte colony-stimulating factor (G-CSF) and/or the number of apheresis days without decreasing of PBSCs yield. Therefore, we have started to collect G-CSF induced PBSCs on day 4 instead of on day 5. So, we retrospectively aimed to investigate the results of this 4-day G-CSF administration.

View Article and Find Full Text PDF
Article Synopsis
  • Granulocyte transfusions are used for patients with severe neutropenia and infections resistant to standard treatments, with higher granulocyte doses leading to better outcomes.
  • A study analyzed data from 312 granulocyte collections to determine how donor characteristics like age, gender, and baseline blood counts affect the efficiency of granulocyte mobilization.
  • Results showed younger donors had better mobilization efficiency, with female donors having higher platelet counts while the donor's age was negatively correlated with mobilization efficiency.
View Article and Find Full Text PDF

Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis characterized by painful skin ulcers. Treatment typically involves systemic corticosteroids, calcineurin inhibitors, or tumor necrosis factor-alpha inhibitors. Currently, treatment guidelines are not well established, making it important to consider alternative options in complicated cases.

View Article and Find Full Text PDF
Article Synopsis
  • Perioperative FEC therapy is a common treatment for breast cancer, but over 20% of patients experience febrile neutropenia (FN), which pegfilgrastim is often used to prevent.
  • A study on pegfilgrastim's long-term safety found no significant differences in blood cell counts or long-term effects after one year of use.
  • Pegfilgrastim administration significantly reduced the incidence of FN (6.5% with pegfilgrastim vs. 22.8% without), indicating it can be safely used for one year in breast cancer patients undergoing chemotherapy.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!